Recent advances in emerging PCOS therapies

Recent advances in emerging PCOS therapies

Polycystic ovary syndrome is a prevalent endocrinopathy involving androgen excess, and anovulatory infertility. The disorder is also associated with many comorbidities such as obesity and hyperinsulinemia, and an increased risk of cardiovascular complications. Reproductive, endocrine, and metabolic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current opinion in pharmacology 2023-02, Vol.68, p.102345-102345, Article 102345
Hauptverfasser: Glendining, Kelly A., Campbell, Rebecca E.
Format: Artikel
Sprache:eng
Schlagworte:
Androgens
Comorbidity
Female
Humans
Insulin Resistance
Obesity - complications
Obesity - drug therapy
Polycystic Ovary Syndrome - complications
Polycystic Ovary Syndrome - drug therapy
Polycystic Ovary Syndrome - metabolism
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 102345
container_issue
container_start_page 102345
container_title Current opinion in pharmacology
container_volume 68
creator Glendining, Kelly A.
Campbell, Rebecca E.
description Polycystic ovary syndrome is a prevalent endocrinopathy involving androgen excess, and anovulatory infertility. The disorder is also associated with many comorbidities such as obesity and hyperinsulinemia, and an increased risk of cardiovascular complications. Reproductive, endocrine, and metabolic symptoms are highly variable, with heterogenous phenotypes adding complexity to clinical management of symptoms. This review highlights recent findings regarding emerging therapies for treating polycystic ovary syndrome, including i) pharmacological agents to target androgen excess, ii) modulation of kisspeptin signalling to target central neuroendocrine dysregulation, and iii) novel insulin sensitisers to combat peripheral metabolic dysfunction.
doi_str_mv 10.1016/j.coph.2022.102345
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2762816917</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1471489222001722</els_id><sourcerecordid>2762816917</sourcerecordid><originalsourceid>FETCH-LOGICAL-c286t-82b3bb6ef75fbfdb53591a79c04581f463c79525a695a93b3fce130eb688d4763</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMotlZfwIXMUoSpuUySCbiR4g0KFS_rkGTOtCmdi8m04Ns7ZaxLV-dw-P4fzofQJcFTgom4XU9d066mFFPaHyjL-BEak0ySNFOSHR_2XNEROotxjTHhjMlTNGJCUEIlHqObN3BQd4kpdqZ2EBNfJ1BBWPp6mbzOFu9Jt4JgWg_xHJ2UZhPh4ndO0Ofjw8fsOZ0vnl5m9_PU0Vx0aU4ts1ZAKXlpy8JyxhUxUjmc8ZyUmWBOKk65EYobxSwrHRCGwYo8LzIp2ARdD71taL62EDtd-ehgszE1NNuoqRQ0J0IR2aN0QF1oYgxQ6jb4yoRvTbDeO9JrvXek94704KgPXf32b20FxV_kIKUH7gYA-i93HoKOzkNvp_ABXKeLxv_X_wPLZ3WK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2762816917</pqid></control><display><type>article</type><title>Recent advances in emerging PCOS therapies</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Glendining, Kelly A. ; Campbell, Rebecca E.</creator><creatorcontrib>Glendining, Kelly A. ; Campbell, Rebecca E.</creatorcontrib><description>Polycystic ovary syndrome is a prevalent endocrinopathy involving androgen excess, and anovulatory infertility. The disorder is also associated with many comorbidities such as obesity and hyperinsulinemia, and an increased risk of cardiovascular complications. Reproductive, endocrine, and metabolic symptoms are highly variable, with heterogenous phenotypes adding complexity to clinical management of symptoms. This review highlights recent findings regarding emerging therapies for treating polycystic ovary syndrome, including i) pharmacological agents to target androgen excess, ii) modulation of kisspeptin signalling to target central neuroendocrine dysregulation, and iii) novel insulin sensitisers to combat peripheral metabolic dysfunction.</description><identifier>ISSN: 1471-4892</identifier><identifier>EISSN: 1471-4973</identifier><identifier>DOI: 10.1016/j.coph.2022.102345</identifier><identifier>PMID: 36621270</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Androgens ; Comorbidity ; Female ; Humans ; Insulin Resistance ; Obesity - complications ; Obesity - drug therapy ; Polycystic Ovary Syndrome - complications ; Polycystic Ovary Syndrome - drug therapy ; Polycystic Ovary Syndrome - metabolism</subject><ispartof>Current opinion in pharmacology, 2023-02, Vol.68, p.102345-102345, Article 102345</ispartof><rights>2022 Elsevier Ltd</rights><rights>Copyright © 2022 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c286t-82b3bb6ef75fbfdb53591a79c04581f463c79525a695a93b3fce130eb688d4763</citedby><cites>FETCH-LOGICAL-c286t-82b3bb6ef75fbfdb53591a79c04581f463c79525a695a93b3fce130eb688d4763</cites><orcidid>0000-0002-0309-532X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.coph.2022.102345$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3538,27906,27907,45977</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36621270$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Glendining, Kelly A.</creatorcontrib><creatorcontrib>Campbell, Rebecca E.</creatorcontrib><title>Recent advances in emerging PCOS therapies</title><title>Current opinion in pharmacology</title><addtitle>Curr Opin Pharmacol</addtitle><description>Polycystic ovary syndrome is a prevalent endocrinopathy involving androgen excess, and anovulatory infertility. The disorder is also associated with many comorbidities such as obesity and hyperinsulinemia, and an increased risk of cardiovascular complications. Reproductive, endocrine, and metabolic symptoms are highly variable, with heterogenous phenotypes adding complexity to clinical management of symptoms. This review highlights recent findings regarding emerging therapies for treating polycystic ovary syndrome, including i) pharmacological agents to target androgen excess, ii) modulation of kisspeptin signalling to target central neuroendocrine dysregulation, and iii) novel insulin sensitisers to combat peripheral metabolic dysfunction.</description><subject>Androgens</subject><subject>Comorbidity</subject><subject>Female</subject><subject>Humans</subject><subject>Insulin Resistance</subject><subject>Obesity - complications</subject><subject>Obesity - drug therapy</subject><subject>Polycystic Ovary Syndrome - complications</subject><subject>Polycystic Ovary Syndrome - drug therapy</subject><subject>Polycystic Ovary Syndrome - metabolism</subject><issn>1471-4892</issn><issn>1471-4973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKAzEUhoMotlZfwIXMUoSpuUySCbiR4g0KFS_rkGTOtCmdi8m04Ns7ZaxLV-dw-P4fzofQJcFTgom4XU9d066mFFPaHyjL-BEak0ySNFOSHR_2XNEROotxjTHhjMlTNGJCUEIlHqObN3BQd4kpdqZ2EBNfJ1BBWPp6mbzOFu9Jt4JgWg_xHJ2UZhPh4ndO0Ofjw8fsOZ0vnl5m9_PU0Vx0aU4ts1ZAKXlpy8JyxhUxUjmc8ZyUmWBOKk65EYobxSwrHRCGwYo8LzIp2ARdD71taL62EDtd-ehgszE1NNuoqRQ0J0IR2aN0QF1oYgxQ6jb4yoRvTbDeO9JrvXek94704KgPXf32b20FxV_kIKUH7gYA-i93HoKOzkNvp_ABXKeLxv_X_wPLZ3WK</recordid><startdate>202302</startdate><enddate>202302</enddate><creator>Glendining, Kelly A.</creator><creator>Campbell, Rebecca E.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0309-532X</orcidid></search><sort><creationdate>202302</creationdate><title>Recent advances in emerging PCOS therapies</title><author>Glendining, Kelly A. ; Campbell, Rebecca E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c286t-82b3bb6ef75fbfdb53591a79c04581f463c79525a695a93b3fce130eb688d4763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Androgens</topic><topic>Comorbidity</topic><topic>Female</topic><topic>Humans</topic><topic>Insulin Resistance</topic><topic>Obesity - complications</topic><topic>Obesity - drug therapy</topic><topic>Polycystic Ovary Syndrome - complications</topic><topic>Polycystic Ovary Syndrome - drug therapy</topic><topic>Polycystic Ovary Syndrome - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Glendining, Kelly A.</creatorcontrib><creatorcontrib>Campbell, Rebecca E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current opinion in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Glendining, Kelly A.</au><au>Campbell, Rebecca E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent advances in emerging PCOS therapies</atitle><jtitle>Current opinion in pharmacology</jtitle><addtitle>Curr Opin Pharmacol</addtitle><date>2023-02</date><risdate>2023</risdate><volume>68</volume><spage>102345</spage><epage>102345</epage><pages>102345-102345</pages><artnum>102345</artnum><issn>1471-4892</issn><eissn>1471-4973</eissn><abstract>Polycystic ovary syndrome is a prevalent endocrinopathy involving androgen excess, and anovulatory infertility. The disorder is also associated with many comorbidities such as obesity and hyperinsulinemia, and an increased risk of cardiovascular complications. Reproductive, endocrine, and metabolic symptoms are highly variable, with heterogenous phenotypes adding complexity to clinical management of symptoms. This review highlights recent findings regarding emerging therapies for treating polycystic ovary syndrome, including i) pharmacological agents to target androgen excess, ii) modulation of kisspeptin signalling to target central neuroendocrine dysregulation, and iii) novel insulin sensitisers to combat peripheral metabolic dysfunction.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>36621270</pmid><doi>10.1016/j.coph.2022.102345</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-0309-532X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1471-4892
ispartof Current opinion in pharmacology, 2023-02, Vol.68, p.102345-102345, Article 102345
issn 1471-4892
1471-4973
language eng
recordid cdi_proquest_miscellaneous_2762816917
source MEDLINE; Elsevier ScienceDirect Journals
subjects Androgens
Comorbidity
Female
Humans
Insulin Resistance
Obesity - complications
Obesity - drug therapy
Polycystic Ovary Syndrome - complications
Polycystic Ovary Syndrome - drug therapy
Polycystic Ovary Syndrome - metabolism
title Recent advances in emerging PCOS therapies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T11%3A06%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20advances%20in%20emerging%20PCOS%20therapies&rft.jtitle=Current%20opinion%20in%20pharmacology&rft.au=Glendining,%20Kelly%20A.&rft.date=2023-02&rft.volume=68&rft.spage=102345&rft.epage=102345&rft.pages=102345-102345&rft.artnum=102345&rft.issn=1471-4892&rft.eissn=1471-4973&rft_id=info:doi/10.1016/j.coph.2022.102345&rft_dat=%3Cproquest_cross%3E2762816917%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2762816917&rft_id=info:pmid/36621270&rft_els_id=S1471489222001722&rfr_iscdi=true